AR127273A1 - Anticuerpos biespecíficos que se unen específicamente a cd47 y her2 y usos de los mismos - Google Patents
Anticuerpos biespecíficos que se unen específicamente a cd47 y her2 y usos de los mismosInfo
- Publication number
- AR127273A1 AR127273A1 ARP220102710A ARP220102710A AR127273A1 AR 127273 A1 AR127273 A1 AR 127273A1 AR P220102710 A ARP220102710 A AR P220102710A AR P220102710 A ARP220102710 A AR P220102710A AR 127273 A1 AR127273 A1 AR 127273A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- her2
- Prior art date
Links
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 title abstract 6
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 title abstract 6
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title abstract 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La invención se relaciona con novedosos anticuerpos biespecíficos, que comprenden al menos un dominio de unión capaz de unirse específicamente a CD47 y al menos un dominio de unión capaz de unirse específicamente a HER2. La invención se relaciona además con métodos de producción de estos anticuerpos biespecíficos y a método de uso de los mismos. Reivindicación 1: Un anticuerpo biespecífico comprende (a) al menos un dominio de unión a antígeno capaz de unirse específicamente a CD47, y (b) al menos un dominio de unión a antígeno capaz de unirse específicamente a HER2, en donde el dominio de unión a antígeno capaz de unirse específicamente a CD47 comprende un VH y un VL, en donde el VH del dominio de unión al antígeno capaz de unirse específicamente a CD47 comprende HCDR1 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 11, HCDR2 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 12, y HCDR3 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 13 o 17 o 21, y el VL del dominio de unión a antígeno capaz de unirse específicamente a CD47 comprende LCDR1 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 14, LCDR2 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 15 o 18 o 22, y LCDR3 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 16.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021122856 | 2021-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127273A1 true AR127273A1 (es) | 2024-01-03 |
Family
ID=85803940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102710A AR127273A1 (es) | 2021-10-09 | 2022-10-06 | Anticuerpos biespecíficos que se unen específicamente a cd47 y her2 y usos de los mismos |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR127273A1 (es) |
| TW (1) | TW202330627A (es) |
| WO (1) | WO2023056970A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR121805A1 (es) * | 2020-04-10 | 2022-07-13 | Hutchison Medipharma Ltd | Anticuerpo anti-cd47 y usos del mismo |
| CN120441709B (zh) * | 2025-07-02 | 2025-09-16 | 中国药科大学 | 一种靶向cd47和her2的双特异性抗体及其制备方法、应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122004000008I1 (de) * | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| CN105189557A (zh) * | 2013-03-15 | 2015-12-23 | 默克专利有限公司 | 四价双特异性抗体 |
| PL3519437T3 (pl) * | 2016-09-30 | 2022-01-17 | F. Hoffmann-La Roche Ag | Przeciwciała dwuswoiste przeciwko p95HER2 |
| CN112745392B (zh) * | 2019-10-30 | 2022-07-01 | 上海洛启生物医药技术有限公司 | 抗pd-l1/cd47双特异性抗体及其用途 |
| AR121805A1 (es) * | 2020-04-10 | 2022-07-13 | Hutchison Medipharma Ltd | Anticuerpo anti-cd47 y usos del mismo |
-
2022
- 2022-10-06 AR ARP220102710A patent/AR127273A1/es unknown
- 2022-10-07 TW TW111138266A patent/TW202330627A/zh unknown
- 2022-10-09 WO PCT/CN2022/124084 patent/WO2023056970A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| TW202330627A (zh) | 2023-08-01 |
| WO2023056970A1 (en) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| PE20240363A1 (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
| AR123480A1 (es) | Moléculas de unión terapéuticas | |
| AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
| IL273841B1 (en) | Antibodies targeting cd137 and methods of use thereof | |
| AR073232A1 (es) | Anticuerpos anti-il-17a/f biespecificos y con reactividad cruzada | |
| AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos | |
| CO6331370A2 (es) | Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| PE20221337A1 (es) | Anticuerpos trem2 y usos de estos | |
| PE20230389A1 (es) | Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas | |
| AR125212A1 (es) | Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas | |
| AR102417A1 (es) | Anticuerpos biespecíficos anti-tnf- / anti-il-23 | |
| PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
| AR114281A1 (es) | Anticuerpos anti-klk5 y métodos de uso | |
| AR127273A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y her2 y usos de los mismos | |
| MX2024015072A (es) | Anticuerpos anti-egfr/met y usos de los mismos | |
| PE20230682A1 (es) | Anticuerpo anti-ox40 y usos del mismo | |
| AR123912A2 (es) | ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |